通过CRISPR-Cas9进行基因治疗的各种技术和方法及其在治疗2型糖尿病中的药理学和介入治疗的现状。

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Current diabetes reviews Pub Date : 2024-01-01 DOI:10.2174/0115733998263079231011073803
Pranay Wal, Namra Aziz, Harshit Prajapati, Shashank Soni, Ankita Wal
{"title":"通过CRISPR-Cas9进行基因治疗的各种技术和方法及其在治疗2型糖尿病中的药理学和介入治疗的现状。","authors":"Pranay Wal, Namra Aziz, Harshit Prajapati, Shashank Soni, Ankita Wal","doi":"10.2174/0115733998263079231011073803","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is frequently referred to as a \"lifestyle illness\". In 2000, India (31.7 million) had the greatest global prevalence of diabetes mellitus, followed by China (20.8 million), the United States (17.7 million), and other countries. In recent years, the treatment of gene therapy (T2DM) has attracted intensive interest.</p><p><strong>Objective: </strong>We aimed to critically review the literature on the various techniques and methods, which may be a possible novel approach through the gene therapy CRISPR Cas9 and some other gene editing techniques for T2DM. Interventional and pharmacological approaches for the treatment of T2DM were also included to identify novel therapies for its treatment.</p><p><strong>Method: </strong>An extensive literature survey was done on databases like PubMed, Elsevier, Science Direct and Springer.</p><p><strong>Conclusion: </strong>It can be concluded from the study that recent advancements in gene-editing technologies, such as CRISPR Cas9, have opened new avenues for the development of novel therapeutic approaches for T2DM. CRISPR Cas9 is a powerful tool that enables precise and targeted modifications of the genome.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e201023222414"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current Landscape of Various Techniques and Methods of Gene Therapy through CRISPR Cas9 along with its Pharmacological and Interventional Therapies in the Treatment of Type 2 Diabetes Mellitus.\",\"authors\":\"Pranay Wal, Namra Aziz, Harshit Prajapati, Shashank Soni, Ankita Wal\",\"doi\":\"10.2174/0115733998263079231011073803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is frequently referred to as a \\\"lifestyle illness\\\". In 2000, India (31.7 million) had the greatest global prevalence of diabetes mellitus, followed by China (20.8 million), the United States (17.7 million), and other countries. In recent years, the treatment of gene therapy (T2DM) has attracted intensive interest.</p><p><strong>Objective: </strong>We aimed to critically review the literature on the various techniques and methods, which may be a possible novel approach through the gene therapy CRISPR Cas9 and some other gene editing techniques for T2DM. Interventional and pharmacological approaches for the treatment of T2DM were also included to identify novel therapies for its treatment.</p><p><strong>Method: </strong>An extensive literature survey was done on databases like PubMed, Elsevier, Science Direct and Springer.</p><p><strong>Conclusion: </strong>It can be concluded from the study that recent advancements in gene-editing technologies, such as CRISPR Cas9, have opened new avenues for the development of novel therapeutic approaches for T2DM. CRISPR Cas9 is a powerful tool that enables precise and targeted modifications of the genome.</p>\",\"PeriodicalId\":10825,\"journal\":{\"name\":\"Current diabetes reviews\",\"volume\":\" \",\"pages\":\"e201023222414\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current diabetes reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115733998263079231011073803\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733998263079231011073803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:2型糖尿病(T2DM)通常被称为“生活方式疾病”。2000年,印度(3170万)是全球糖尿病患病率最高的国家,其次是中国(2080万)、美国(1770万)和其他国家。近年来,基因治疗(T2DM)引起了人们的极大兴趣。目的:我们旨在批判性地回顾有关各种技术和方法的文献,这些技术和方法可能是通过CRISPR-Cas9和其他一些基因编辑技术治疗T2DM的一种新方法。还包括治疗T2DM的介入和药理学方法,以确定其治疗的新疗法。方法:在PubMed、Elsevier、Science Direct和Springer等数据库上进行了广泛的文献调查。结论:从研究中可以得出结论,CRISPR-Cas9等基因编辑技术的最新进展为开发新的T2DM治疗方法开辟了新的途径。CRISPR-Cas9是一种强大的工具,可以对基因组进行精确和有针对性的修饰。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Current Landscape of Various Techniques and Methods of Gene Therapy through CRISPR Cas9 along with its Pharmacological and Interventional Therapies in the Treatment of Type 2 Diabetes Mellitus.

Background: Type 2 diabetes mellitus (T2DM) is frequently referred to as a "lifestyle illness". In 2000, India (31.7 million) had the greatest global prevalence of diabetes mellitus, followed by China (20.8 million), the United States (17.7 million), and other countries. In recent years, the treatment of gene therapy (T2DM) has attracted intensive interest.

Objective: We aimed to critically review the literature on the various techniques and methods, which may be a possible novel approach through the gene therapy CRISPR Cas9 and some other gene editing techniques for T2DM. Interventional and pharmacological approaches for the treatment of T2DM were also included to identify novel therapies for its treatment.

Method: An extensive literature survey was done on databases like PubMed, Elsevier, Science Direct and Springer.

Conclusion: It can be concluded from the study that recent advancements in gene-editing technologies, such as CRISPR Cas9, have opened new avenues for the development of novel therapeutic approaches for T2DM. CRISPR Cas9 is a powerful tool that enables precise and targeted modifications of the genome.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current diabetes reviews
Current diabetes reviews ENDOCRINOLOGY & METABOLISM-
CiteScore
6.30
自引率
0.00%
发文量
158
期刊介绍: Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
期刊最新文献
Development and Novel Therapeutics in Diabetic Retinopathy. The Effect of COVID-19 Lockdown Among Adolescents with Type 1 Diabetes: A Systematic Review and Meta-Analysis. Ultrasound Evaluations of Ankle and Foot Muscles in Diabetic Peripheral Neuropathy Systematic Review with Meta-Analysis. In-Vitro and In-Silico Studies of Brevifoliol Ester Analogues against Insulin Resistance Condition. Efficacy of Adjunctive Local Antimicrobials to Non-Surgical Periodontal Therapy in Pocket Reduction and Glycemic Control of Patients with Type 2 Diabetes: A Network Meta-Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1